Q1 EPS Estimate for Bio-Rad Laboratories Reduced by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for Bio-Rad Laboratories in a research report issued on Thursday, March 6th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $1.98 for the quarter, down from their prior forecast of $2.29. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.91 EPS, FY2025 earnings at $10.70 EPS, Q1 2026 earnings at $3.22 EPS, Q2 2026 earnings at $2.88 EPS and Q3 2026 earnings at $3.01 EPS.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%.

A number of other brokerages have also commented on BIO. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $251.17 on Monday. The business’s fifty day simple moving average is $316.63 and its 200 day simple moving average is $329.48. The firm has a market capitalization of $7.04 billion, a P/E ratio of -3.86 and a beta of 0.99. Bio-Rad Laboratories has a 12 month low of $244.19 and a 12 month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Institutional Trading of Bio-Rad Laboratories

Hedge funds have recently made changes to their positions in the company. Venturi Wealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after buying an additional 87 shares during the period. GeoWealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock valued at $31,000 after buying an additional 72 shares during the period. Gladius Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the third quarter valued at $32,000. Picton Mahoney Asset Management grew its position in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares in the last quarter. Finally, Asset Planning Inc purchased a new stake in Bio-Rad Laboratories during the 4th quarter worth about $33,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.